<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579279</url>
  </required_header>
  <id_info>
    <org_study_id>M11-210</org_study_id>
    <secondary_id>2011-003939-56</secondary_id>
    <nct_id>NCT01579279</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic
      neuropathic pain. People with diabetes can, over time develop nerve damage throughout the
      body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms,
      feet and legs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double blind, randomized, active- and placebo-controlled 13-week study. Duloxetine is added
      to evaluate assay sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study Stopped
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Average Pain Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly mean of 24-hour average pain score measured by a 11-point Numeric Rating Scale completed on subject's daily diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptom Inventory</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measures severity of common neuropathic pain qualities (burning, pressure, squeezing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>12 weeks</time_frame>
    <description>Captures the subject's evaluation of his/her overall general impression of feeling since beginning study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>12 weeks</time_frame>
    <description>Capture the subject's severity of pain and interference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Impact on Quality of Life Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Captures the subject's assessment of neuropathic pain and the effect it has on the quality of daily life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQuality of Life - 5 Dimension -5 Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Capture's the subject's mobility, self-care, usual activity, pain/discomfort and anxiety/depression</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diabetic Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>ABT-652 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-652 capsules - twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-652 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-652 capsules twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-652 12 mg - 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-652 capsules twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine capsules once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-652 6 mg</intervention_name>
    <description>6 mg capsules</description>
    <arm_group_label>ABT-652 6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-652 12 mg</intervention_name>
    <description>12 mg capsules</description>
    <arm_group_label>ABT-652 12 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-652 12 mg - 18 mg</intervention_name>
    <description>12 mg - 18 mg capsules</description>
    <arm_group_label>ABT-652 12 mg - 18 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine capsules</description>
    <arm_group_label>Duloxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is between the ages of 18-75 years with a diagnosis of diabetes mellitus and
             must have a diagnosis of painful distal symmetric diabetic polyneuropathy and presence
             of ongoing pain due to diabetic peripheral neuropathy for at least 6 months.

          -  Subject must have a mean average score of greater than 4 on the 24 hour average pain
             score (0-10 numerical rating scale) prior to the Baseline Visit.

          -  Subject has been on a medication for diabetic neuropathic pain for the past 3 months.

        Exclusion Criteria:

          -  Subject has clinically symptomatic neuropathic pain conditions that cannot be
             distinguished from Diabetic Neuropathic Pain or interfere with the pain assessments of
             Diabetic Neuropathic Pain.

          -  A subject has newly diagnosed or clinically significant medical conditions or mental
             disorders that would preclude participation or would interfere with Diabetic
             Neuropathic Pain assessments or other functions.

          -  Subject has clinically significant abnormalities in clinical laboratory tests.

          -  Subject has taken an opioid chronically, excluding tramadol within the last 3 months
             prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfram Nothaft, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62887</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62824</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63710</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62884</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62826</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63703</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73913</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62886</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic neuropathic pain</keyword>
  <keyword>Active controlled phase 2 study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

